Precision for Medicine and SOPHiA GENETICS announced a strategic partnership today aimed at enhancing biomarker discovery and precision medicine services for biopharma companies. The collaboration, revealed on April 8, 2025, will integrate SOPHiA's advanced AI-driven analytics platform with Precision's clinical trial solutions to accelerate drug development and deliver targeted therapies more efficiently.
Under the agreement, Precision for Medicine will incorporate the SOPHiA DDM™ Platform into its service offerings, providing pharmaceutical clients with enhanced capabilities for biomarker discovery, clinical trial assays, and advanced data analysis algorithms. This integration is expected to significantly improve clinical trial design, patient stratification, and data interpretation.
"We're thrilled to partner with SOPHiA GENETICS to integrate the SOPHiA DDM™ Platform and integrate MSK-ACCESS® powered with SOPHiA DDM™ into our offering," said Darren Davis, PhD, Senior Vice President at Precision for Medicine. "By leveraging AI-powered algorithms and machine learning, we can pinpoint biomarkers and genomic signatures that enable more efficient, targeted trials and improve therapeutic efficacy."
Enhanced Multimodal Data Analysis
The partnership will leverage SOPHiA DDM™'s AI-driven algorithms to analyze complex multimodal data, including genomic, radiomic, and clinical information. This capability is particularly valuable for precision medicine initiatives in oncology, rare diseases, and genetic disorders, where understanding specific genomic characteristics is crucial for developing targeted therapeutic approaches.
Biopharma companies will be able to identify and select the most appropriate patient populations for clinical trials, potentially reducing enrollment times and improving trial success rates. The platform's ability to process and interpret diverse data types provides researchers with deeper insights into disease mechanisms and potential treatment responses.
Advanced Liquid Biopsy Capabilities
A key component of the partnership is the integration of MSK-ACCESS® powered with SOPHiA DDM™, an innovative liquid biopsy test currently being deployed globally with support from AstraZeneca. This technology will now be available as a Precision for Medicine service for biopharma clients.
The genomically rich data generated by this test will enable retrospective clinical trial data analysis and improve patient stratification. Companies can refine their clinical trial designs by analyzing how patients responded to previous treatments, allowing for more evidence-based drug development strategies and improved patient recruitment.
Streamlined End-to-End Services
Through this collaboration, Precision for Medicine will provide comprehensive services including wet lab testing, data analysis, and clinical trial support under one umbrella. This integrated approach allows pharmaceutical companies to work with a single solution provider throughout their drug development programs.
"Our collaboration with Precision for Medicine enables us to expand the reach and impact of our SOPHiA DDM™ Platform and deliver real-time actionable insights across the clinical trial continuum," said Ross Muken, President at SOPHiA GENETICS. "By combining our AI-powered Platform with Precision for Medicine's cutting-edge clinical trial solutions, we can deliver comprehensive, data-driven capabilities to biopharma companies, accelerating the path to market for precision therapies."
Implications for Drug Development
The partnership creates a powerful solution that combines Precision for Medicine's established clinical trial expertise with SOPHiA GENETICS' AI-based genomic analysis tools. This integration is expected to enable more efficient progression from preclinical research to market readiness, potentially reducing development timelines and costs.
For pharmaceutical companies, the collaboration offers a competitive advantage in the ability to bring innovative therapies to patients faster and improve market positioning. The enhanced capabilities for biomarker discovery and patient stratification are particularly valuable in the increasingly competitive precision medicine landscape.
Focus on Personalized Medicine
This partnership represents a significant advancement in precision medicine, providing pharmaceutical researchers with sophisticated tools to better understand patient genomic profiles and develop personalized treatments for complex diseases. The collaboration enables companies to tailor treatments based on specific genomic characteristics, potentially enhancing treatment outcomes and patient satisfaction.
The patient-centric approach aims to drive breakthroughs in oncology, rare diseases, and other areas with high unmet medical needs. By improving the ability to match patients with appropriate therapies based on their genetic profiles, the partnership could contribute to more effective treatments and better clinical outcomes.
Precision for Medicine, part of Precision Medicine Group, operates in 40 locations globally with 3,400 employees across North America, Europe, and Asia-Pacific. SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company focused on expanding access to data-driven medicine through AI-powered analysis of complex genomic and multimodal data.
